ClinicalTrials.gg
CompletedNCT06745518Updated Aug 7, 2025

A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

A Phase 2 interventional study of TS-172 and Placebo in Hyperphosphatemia Patients on Hemodialysis, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.

Enrollment
25th of 36
62 · median 117
Started
2025
with 2 others
Phase 2
11 of 41
none open now
Registered
36th of 41
by date
Lead sponsor
7 of 41
Taisho Pharmaceutical Co., Ltd.

Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 25th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 in phase 2, and was the 36th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Hyperphosphatemia with a site in Japan, or all of them as a file.
02

Study summary

A phase 2, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

03

Conditions studied

  • Hyperphosphatemia Patients on Hemodialysis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to Visit 1 (Week -3)
  2. Patients aged >= 18 years at the time of obtaining
  3. Patients with a serum phosphorus concentration of >= 5.5 mg/dL and \< 10.0 mg/dL at Visit 1 (Week -3)
  4. Patients who have been prescribed at least one phosphate binder within the approved dosage, and the prescribed drug and dosage regimen should have been unchanged during the last 2 weeks prior to Visit 1 (Week -3)

Exclusion criteria

Exclusion Criteria:

  1. Patients with confirmed serum intact PTH concentration >500 pg/mL from Visit 1 (Week -3) to Visit 4 (Week 0)
  2. Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    TS-172

    Drug: TS-172

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugTS-172

    oral administration of TS-172 20\~60 mg/day

  • DrugPlacebo

    oral administration of placebo

06

What researchers measure

Primary outcomes

  1. Achievement rate of the target serum phosphorus level

    Time frame: Week 8

Secondary outcomes

  1. Change from baseline in serum concentration of phosphorus

    Time frame: Up to Week 8

  2. Concentration of corrected serum calcium

    Time frame: Up to Week 8

  3. Serum Ca × P product

    Time frame: Up to Week 8

07

Study locations

1 site
  • Taisho Pharmaceutical Co., Ltd selected site
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jul 2025, 6 months.

Of 13 phase 2 interventional studies under Hyperphosphatemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 10. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
Jan 6, 2025
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 22, 2025
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06745518
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Jan 6, 2025
Primary completion
Jul 15, 2025
Completion
Jul 22, 2025
Last update
Aug 7, 2025

Study contacts

Taisho Director
study director · Taisho Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TS-172

Start the discussion